{
    "eid": "2-s2.0-85075100732",
    "title": "Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non\u2013small cell lung cancer",
    "cover-date": "2019-11-15",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Jhanelle E. Gray",
        "Isamu Okamoto",
        "Virote Sriuranpong",
        "Johan Vansteenkiste",
        "Fumio Imamura",
        "Jong Seok Lee",
        "Yong Kek Pang",
        "Manuel Cobo",
        "Kazuo Kasahara",
        "Ying Cheng",
        "Naoyuki Nogami",
        "Eun Kyung Cho",
        "Wu Chou Su",
        "Guili Zhang",
        "Xiangning Huang",
        "Xiaocheng Li-Sucholeiki",
        "Brian Lentrichia",
        "Simon Dearden",
        "Suzanne Jenkins",
        "Matilde Saggese",
        "Yuri Rukazenkov",
        "Suresh S. Ramalingam"
    ],
    "citedby-count": 84,
    "ref-count": 46,
    "ref-list": [
        "Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update",
        "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",
        "Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients",
        "Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation",
        "Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors",
        "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers",
        "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer",
        "CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non\u2013small-cell lung cancer",
        "CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: Data from a randomized phase III Trial (AURA3)",
        "Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer",
        "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer",
        "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors",
        "EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291",
        "First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study",
        "Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib",
        "Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: A meta-analysis",
        "EGFR mutation analysis for prospective patient selection in two phase II registration studies of osimertinib",
        "Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer",
        "EGFR T790M mutation testing within the osimertinib AURA phase I study",
        "A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer",
        "A comparison of EGFR mutation testing methods in lung carcinoma: Direct sequencing, real-time PCR and immunohistochemistry",
        "Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing",
        "Significant improvement in detecting BRAF, KRAS, and EGFR mutations using next-generation sequencing as compared with FDA-Cleared Kits",
        "Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy)",
        "Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: Retrospective testing of specimens from the EURTAC trial",
        "The clinical and economic impact of inaccurate EGFR mutation tests in the treatment of metastatic non-small cell lung cancer",
        "Influence of tumour micro-environment heterogeneity on therapeutic response",
        "A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer",
        "Uncommon EGFR mutations in advanced non-small cell lung cancer",
        "Liquid biopsies: Genotyping circulating tumor DNA",
        "Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer",
        "Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy",
        "Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial",
        "Comprehensive genomic profiling facilitates implementation of the national comprehensive cancer network guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials",
        "Current and future molecular testing in NSCLC, what can we expect from new sequencing technologies?",
        "Noninvasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA",
        "Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients",
        "The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer",
        "Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients",
        "Liquid biopsy: Advances, limitations and clinical applications",
        "Cons: Can liquid biopsy replace tissue biopsy?-the US experience"
    ],
    "affiliation": [
        {
            "affiliation-city": "Cambridge",
            "@id": "60004219",
            "affilname": "AstraZeneca",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004219",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Seongnam",
            "@id": "60199632",
            "affilname": "Gachon University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199632",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Osaka",
            "@id": "60138477",
            "affilname": "Osaka International Cancer Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138477",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Seongnam",
            "@id": "60098516",
            "affilname": "Seoul National University Bundang Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60098516",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Changchun",
            "@id": "60082194",
            "affilname": "Jilin Provincial Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082194",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Tainan",
            "@id": "60073386",
            "affilname": "National Cheng Kung University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073386",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Leuven",
            "@id": "60031069",
            "affilname": "KU Leuven\u2013 University Hospital Leuven",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031069",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Fukuoka",
            "@id": "60021786",
            "affilname": "Kyushu University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021786",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Pleasanton",
            "@id": "60020160",
            "affilname": "Roche Molecular Systems",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020160",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Kanazawa",
            "@id": "60016178",
            "affilname": "Kanazawa University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016178",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Tokyo",
            "@id": "60014072",
            "affilname": "National Hospital Organization, Japan",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60014072",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60013665",
            "affilname": "University of Malaya Medical Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013665",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Malaga",
            "@id": "60013124",
            "affilname": "Hospital Regional Universitario Carlos Haya",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013124",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Tampa",
            "@id": "60004803",
            "affilname": "Moffitt Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004803",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Atlanta",
            "@id": "60002339",
            "affilname": "Emory University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002339",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60000656",
            "affilname": "Seoul National University College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000656",
            "affiliation-country": "South Korea"
        }
    ],
    "funding": [
        "Ashfield Company",
        "Helen Brown",
        "Lilly, Celgene, and Takeda",
        "Roche Molecular Systems Inc.",
        "UDG Healthcare plc",
        "Bristol-Myers Squibb",
        "Eli Lilly",
        "AstraZeneca",
        "Genentech",
        "Merck",
        "Novartis",
        "Janssen",
        "Array"
    ]
}